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Note
Biosimilar Regulation: Bringing the United
States Up To Speed with Other Markets
Vinita Banthia*
ABSTRACT
In light of the expected end of patent terms for many large
molecule drugs called biologics, there has been a rise in the
development of biosimilars—non-branded, copycat versions of
biologics. Unlike generic drugs, which are non-branded versions
of small molecule chemical drugs, biosimilars are not identical
to the biologic they reference, since biologics are derived from
living organisms and are often injected into the patient, which
makes them impossible to replicate perfectly. Despite their
complexities, biologics exist to treat important diseases such as
AIDS, Alzheimer’s, and cancer. In 2010, the Biologics Price
Competition and Innovation Act (Biosimilars Act) was added to
the Public Health Service Act (PHS Act), outlining the approval
process and regulatory plan for biosimilars. The Food and Drug
Administration (FDA) subsequently released six Draft Guidance
Documents (Guidance Documents) to clarify some of the
provisions in the Biosimilars Act and to define ambiguous terms
and phrases. Although biosimilars have been an important
treatment option in many countries for over twenty years, none
have been approved in the United States.
On March 15, 2015, the FDA approved Sandoz’s Zarxio
after the FDA’s Oncological Drugs Advisory Committee
recommended approval by the agency. However, on May 5, 2015,
the Appeals Court for the Federal Circuit granted an injunction
preventing Sandoz from selling Zarxio until further arguments
are heard. The FDA may be progressing toward a more lenient
view on biosimilar approvals; however, the court’s injunction
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indicates that the United States lags in its exploitation of
biosimilars, and revisions to the current law will allow for a
robust biosimilars market. Previous scholarship has outlined
the barriers to biosimilar acceptance in the United States and
acknowledged the potential benefit of higher approval rates.
This Note analyzes the Biosimilars Act and the Guidance
Documents, and proposes revisions to these documents and to
the current structure of the insurance and health care systems
in relation to biosimilars. These adaptations will allow the
United States to improve access to key medical treatments
across the country and catch up with other biosimilar markets.
I. INTRODUCTION: BIOLOGICS AND THE EMERGENCE
OF BIOSIMILARS
Amgen, a leading U.S. multinational biopharmaceutical
company,1 stated in 2014 that several “leading biologic
medicines, worth an estimated $81 billion in global annual
sales, will lose their patents by 2020.”2 Biologics are a
relatively new genre of medicine, rising in popularity only since
the 1970s.3 They are significantly larger than earlier-developed
drugs such as Tylenol and Prozac, which have simple chemical
compositions and are referred to as “chemical drugs.”4 Unlike
chemical drugs, biologic drugs are derived from living
organisms. Common biologics include “vaccines, blood and
blood components, allergenics, somatic cells, gene therapy,
tissues, and recombinant therapeutic proteins,”5 and they often

1. Amgen is the largest independent biotechnology firm in the world.
Reuters, Amgen Posts Lower-than-Expected Earnings, N.Y. TIMES, Apr. 23,
2014, at B2.
2. AMGEN, BIOLOGICS AND BIOSIMILARS: AN OVERVIEW 12 (2014)
[hereinafter AMGEN OVERVIEW], available at http://www.amgen.com/pdfs
/misc/Biologics_and_Biosimilars_Overview.pdf.
3. Id. at 4.
4. Id. at 4–5. Tylenol (generically referred to as acetaminophen) is a
small molecule drug with the chemical formula C8H9NO2 and a molecular
mass of 151.163 g/mol. Acetaminophen, PUBCHEM, http://pubchem.ncbi.nlm.ni
h.gov/compound/acetaminophen (last visited Apr. 4, 2015). Prozac has a
chemical formula of C17H18F3NO and weighs 309.326 g/mol. Fluoxetine,
PUBCHEM, http://pubchem.ncbi.nlm.nih.gov/compound/fluoxetine (last visited
Apr. 4, 2015).
5. What Are “Biologics” Questions and Answers, U.S. FOOD & DRUG
ADMIN.,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProd
uctsandTobacco/CBER/ucm133077.htm (last updated Apr. 14, 2009).
Allergenic products are biologically derived and “administered to man for the
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need to be injected into the patient.6 Comparing the biologic
Epogen with the small molecule drug aspirin provides a helpful
illustration of the distinction between chemical drugs and
biologics.7 Epogen, made by Amgen, mimics the function of
erythropoietin by producing red blood cells to treat anemia.8
One Epogen molecule is composed of 165 amino acids9 and
weighs approximately 168 times more than a molecule of
aspirin.10
As the patent terms11 for many large molecule drugs come
to an end in the next five years,12 several manufacturers are in
diagnosis, prevention or treatment of allergies.” 21 C.F.R. § 680.1(a) (2011).
They include Allergenic Extracts and Allergen Patch Tests and may be
extracted from sources such as “pollen, insects, . . . mold, food, chemicals, and
animals.” U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY ON THE
CONTENT AND FORMAT OF CHEMISTRY, MANUFACTURING AND CONTROLS
INFORMATION AND ESTABLISHMENT DESCRIPTION INFORMATION FOR AN
ALLERGENIC EXTRACT OR ALLERGEN PATCH TEST 1 (1999), available at
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRe
gulatoryInformation/Guidances/Allergenics/ucm078638.pdf. A somatic cell is
any cell within the body of an organism; it does not include germ-line cells
such as ova and sperm. MICHAEL ROBERTS ET AL., ADVANCED BIOLOGY 633
(2000). “Gene therapy is an experimental technique that uses genes to treat or
prevent disease.” What Is Gene Therapy, GENETICS HOME REFERENCE (Mar.
30, 2015), http://ghr.nlm.nih.gov/handbook/therapy/genetherapy.
6. AMGEN OVERVIEW, supra note 2, at 5.
7. Jason Kanter & Robin Feldman, Understanding and Incentivizing
Biosimilars, 64 HASTINGS L.J. 57, 63–64 (2012). Epogen (also referred to as
Epoetin alfa) has a molecular formula of C815H1317N233O241S5 and weighs
18,396.1 g/mol. Active Ingredient: Epoetin Alfa - Chemistry and Biological
DRUGLIB.COM,
http://www.druglib.com/activeingredient/epoetin
Activity,
_alfa/chembio/ (last visited Apr. 4, 2015) [hereinafter Active Ingredient].
Aspirin only weighs 180.157 g/mol and has the chemical formula C9H8O4.
Aspirin, PUBCHEM (Sept. 16, 2004), http://pubchem.ncbi.nlm.nih.gov
/compound/2244.
8. Kanter & Feldman, supra note 7, at 63.
9. Amino acids are compounds that contain an amino group, –NH2, a
carboxylic acid group, –COOH and a unique side chain that distinguishes each
amino acid. Amino acids are the major building blocks of protein in the human
body. HANS-DIETER JAKUBKE & NORBERT SEWALD, PEPTIDES FROM A TO Z: A
CONCISE ENCYCLOPEDIA 20–21 (2008).
10. Kanter & Feldman, supra note 7, at 64. Aspirin has many functions
including preventing transmission of a pain signal to the brain, preventing
blood clotting, and reducing inflammation. Aspirin does not contain any amino
acids. Aspirin, supra note 7.
11. Patent terms typically last twenty years from the time of filing. 35
U.S.C § 154(a)(2) (2012).
12. See John Carroll, Biosimilars Set to Boom as New Patent Cliff on
(July
22,
2014),
Biologic
Superstars
Looms,
FIERCEBIOTECH
http://www.fiercebiotech.com/story/biosimilars-set-boom-new-patent-cliff-bio
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the process of copying these biologics to produce similar drugs,
referred to as “biosimilars.”13 In the meantime, Congress and
the U.S. Food and Drug Administration (FDA)14 have started
establishing an effective approval pathway and regulation
scheme for these copied biologics.15 A biosimilar is akin to a
“generic” version of a small molecule chemical drug;16 however,
the inability to replicate the biological drugs identically means
that a biosimilar manufacturer can at best produce a similar
molecule, not one identical to the original biologic.17
Although there are risks associated with biosimilars, there
are invaluable benefits to be gained from their development
and the approval process essentially acts as a cost-benefit
analysis for each drug that comes before it.18 In the long run,
the utility of biologics will greatly outweigh the risks, and
today more than 400 biologic medicines are being studied
worldwide for their applicability in treating illnesses such as
HIV/AIDS, Alzheimer’s disease, cancer, anemia, cystic fibrosis,
growth deficiency, diabetes, hemophilia, hepatitis, genital

logic-superstars-looms/2014-07-22 (“AMR [Allied Marketing Research] counted
10 biologics with a collective $60 billion in revenue that will come off patent in
the next four years.”).
13. AMGEN OVERVIEW, supra note 2, at 10–11.
14. The FDA is a federal agency of the United States Department of
Health and Human Services responsible for protecting public health through
regulation of food, pharmaceutical drugs (medications), vaccines, and other
biologic medicines. P’SHIP FOR PUB. SERV., THE STATE OF THE FDA
WORKFORCE 1 (2012), available at http://www.washingtonpost.com/r/2010-20
19/WashingtonPost/2012/11/19/National-Politics/Graphics/PEW_FDA_Public
_19112012.pdf.
15. Carroll, supra note 12 (“$1.3 billion [biosimilar market] base is
expected to swell to $35 billion by 2020 as new products penetrate the market
in North America, Europe and Asia.”); see AMGEN OVERVIEW, supra note 2, at
12, 14. See generally Kanter & Feldman, supra note 7, at 59–60.
16. The Hatch-Waxman Act’s Abbreviated New Drug Application (ANDA)
provisions allow small molecule generic drugs to gain approval through a
simpler process if they demonstrate bioequivalency with the branded drug.
The Biosimilars Act aims to provide a similar, abbreviated pathway for
imitation versions of large molecule drugs or biologics. Drug Price Competition
and Patent Term Restoration (Hatch-Waxman) Act of 1984, 21 U.S.C. § 355(j)
(2012); Katherine N. Addison, The Impact of the Biosimilars Provisions of the
Health Care Reform Bill on Innovation Investments, 10 J. MARSHALL REV.
INTELL. PROP. L. 553, 560–62 (2011).
17. Kanter & Feldman, supra note 7, at 59.
18. Economic Impact Analyses of FDA Regulations, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/Econ
omicAnalyses/ (last updated Feb. 17, 2015).

2015]

BIOSIMILAR REGULATION

883

warts, transplant rejection, autoimmune disorders, and many
others.19 Biosimilars are expected to be up to thirty percent
cheaper than their branded or innovator biologic
counterparts.20 In addition, the competition will drive prices
down further, leading to an expected forty percent price
reduction in the long run.21 Although these reductions will not
compare to those seen with generics,22 they will still increase
access to important, life-saving biologics.23 The increased
incentives and security for biosimilar manufacturers will raise
the amount of research and development in the area, leading to
more knowledge in the field.24 Finally, the increased access to
biologics will allow for more post-market safety and efficacy
studies that will lead to safer drugs over time.25
This Note argues that biosimilars are a valuable area of
drug development, but they are not sufficiently incentivized
due to the arduous regulations and uncertainty in current U.S.
laws and proposes several novel recommendations to address

19. Thomas Morrow & Linda Hull Felcone, Defining the Difference: What
Makes Biologics Unique, 1 BIOTECHNOLOGY HEALTHCARE 24, 24–26, 28–29
(2004); see AMGEN OVERVIEW, supra note 2, at 8. For a description of these
and related genetic disorders, see generally Genetic Disorders—Common
Genetically Inherited Diseases—Alzheimer’s Disease, Cancer, Cystic Fibrosis,
Diabetes, Huntington’s Disease, LIBR. INDEX, http://www.libraryindex.com
/pages/270/Genetic-Disorders.html (last visited Apr. 4, 2015).
20. Peyton Howell, How Much Cheaper Will Biosimilars Be?,
FIERCEPHARMA (Mar. 2, 2012), http://www.fiercepharma.com/story/how-muchcheaper-will-biosimilars-be/2012-03-02.
21. Id.
22. Generic
Versus
Branded
Medicines,
HEALTHSMART,
http://www.healthsmart.com/WellnessResourceCenter/GenericVsBrandDrugs
.aspx (last visited Apr. 4, 2015). The availability of generic drugs currently
saves the U.S. healthcare system over $200 billion each year. GENERIC
PHARM. ASS’N, GENERIC DRUG SAVINGS IN THE U.S. 1 (6th ed. 2014), available
at
http://www.gphaonline.org/media/cms/GPhA_Savings_Report.9.10.14
_FINAL.pdf.
23. Biosimilars Can Help Lower Costs and Increase Access, SANDOZ,
http://www.sandoz-biosimilars.com/biosimilars2/importance.shtml (last visited
Apr. 4, 2015). A 2012 study by the IGES Institute Berlin analyzed the cost
savings from biosimilars in the European Union, and found that it saved
Germany €551 million. The study also gathered data on savings for eight
other European countries and found that the cumulative savings for the eight
countries is expected to be as high as €33 billion by 2020. Id.
24. See id.
25. See AMGEN OVERVIEW, supra note 2, at 21.
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the issue.26 Part I (preceding) has provided background on the
history and importance of biosimilars. Part II addresses the
two issues hindering biosimilar development in the United
States: first, the difficulties associated with regulating
biosimilars, and second, the shortcomings of the current law.
Part III analyzes the current approval process for biosimilars
through an examination of the Biosimilars Act and the FDA
Draft Guidance Documents, and compares it to the approval
process for innovator biologics. Part IV discusses different
solutions to the current system in six subparts. First, this Note
argues that innovator biologics should be given less exclusivity.
Second, this Note advocates requiring fewer studies from
biosimilar applicants. Third, measures should be taken to
ensure biosimilar safety at the earlier stages of development as
opposed to the later, clinical stages. Next, the health care
industry should be involved in the dialogue and highlights
some elements that must be a part of any approval process
regardless of how it is implemented. The fifth subsection
discusses two alternative approaches to addressing the
question of interchangeability and substitution, for pharmacies
and insurance companies. Finally, the last subsection briefly
describes the importance of insurance substitution in terms of
biosimilars coverage.
This Note argues that to give biosimilars a brighter future
in the United States, Congress and the FDA must make several

26. See Kanter & Feldman, supra note 7, at 60–61 (“If we are serious
about reducing the price of biological drugs and encouraging the creation of
biosimilars, we will need to develop a more effective pathway for approval.”);
see also Addison, supra note 16, at 580–82. Addison argues that the FDA has
taken an especially stringent view of the Biosimilars Act and that the Act
itself is open to a more lenient interpretation. Id. This is difficult to predict
since the FDA has not yet approved a biosimilar under the new process, and
there will be more information once there are a few examples to look to.
However, a careful reading of the FDA Guidance Documents and the
Biosimilars Act suggests that the FDA will want to see more rigorous clinical
studies (i.e., efficiency and safety studies) than the Biosimilars Act indicates.
See Public Health Service Act, 42 U.S.C. § 262 (2012) (regulation of biological
products); see also U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
BIOSIMILARS: QUESTIONS AND ANSWERS REGARDING IMPLEMENTATION OF THE
BIOLOGICS PRICE COMPETITION AND INNOVATION ACT OF 2009 (2012)
[hereinafter FDA QUESTIONS AND ANSWERS], available at http://www.fda.gov
/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UC
M273001.pdf. On the other hand, the Biosimilars Act may be more stringent
in other areas such as the requirements for proving interchangeability of a
biosimilar. See § 262; see also FDA QUESTIONS AND ANSWERS, supra.
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revisions to the approval pathway.27 Promoting the
development of biosimilars would be best achieved through a
change in the Biosimilars Act and the FDA Guidance
Documents, in accordance with some of the approval processes
implemented in other countries that have already developed a
pathway.28 An effective biosimilar approval pathway would
necessarily need to strike a balance between ensuring safety
and providing affordable access to biologic medicines.
II. BARRIERS TO MANUFACTURING AND REGULATING
BIOSIMILARS
A. THE COMPLEXITIES OF BIOSIMILARS CREATE A SEVERE
CHALLENGE FOR THEIR DEVELOPMENT AND REGULATION
The complex nature of innovative biologics and
biosimilars29 makes them difficult to manufacture and small
variations in the manufacturing process have the potential to
cause different biological effects in the patient.30 Also, the
patient-specific reactions and side effects to biologics vary
widely compared to small molecule drugs.31
Given the variables in the biologics manufacturing
process—including different genetics of the living components,
and environmental factors such as “light, temperature,
moisture, packaging materials, container closure systems, and
delivery device materials”32—that affect the final product, it is

27. See Addison, supra note 16, at 563–65 (presenting the FDA approval
process for biosimilars); Kanter & Feldman, supra note 7, at 60–61 (discussing
the need for changes to the approval pathway).
28. See, e.g., Addison, supra note 16, at 559 (“Europe appears to be more
receptive to approving biosimilars . . . . The year 2007 marked the beginning of
the biosimilars era in Europe.”).
29. See infra text accompanying note 33.
30. Addison, supra note 16, at 562–64 (“[B]ecause of the complex nature of
biologics compared to traditional chemically synthesized drugs, the new
legislation is quite rigorous . . . . In order to implement the new legislation, the
FDA created the Biosimilar Implementation Committee.”); Joanne Barker,
Biologics for RA: Understanding Risks and Benefits, WEBMD (June 22, 2011),
http://www.webmd.com/rheumatoid-arthritis/features/risks-benefits
(discussing the risks and benefits of using biologics to treat rheumatoid
arthritis).
31. See, e.g., Barker, supra note 30.
32. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: SCIENTIFIC
CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE
PRODUCT 5 (2013) [hereinafter FDA SCIENTIFIC CONSIDERATIONS], available
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well accepted that the prospect of creating an identical biologic
is non-existent sometimes even for the same manufacturer that
made the reference product.33 Several impurities can arise at
various stages of the biologic’s development. First, vaccines and
other biologics are developed on cell substrates,34 and
standardized cell substrates are needed to make consistent
biologics.35 Furthermore, many vaccines are not used
continuously and must be stored for long durations.36 This
requires them to either be safely stockpiled37 or able to be
manufactured consistently in batches.38 Additionally, the cell
bank39 for a particular vaccine may deplete, requiring the
creation of a new cell bank, which may behave differently than
the previous one.40 Hence, while generic drugs are practically
identical to their branded counterparts, biosimilars can only be
similar to their biologic counterparts due to their complex and
organic nature.41
Two researchers, Glenn Begley and Lee Ellis found that
scientists at Amgen were only able to replicate six out of fiftythree (eleven percent) of their pre-clinical research on cancer
therapies.42 The Amgen scientists attempted to replicate a
at
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinfor
mation/guidances/ucm291128.pdf; see AMGEN OVERVIEW, supra note 2, at 34.
33. A company tried to set up two identical laboratories in different
locations and used the same process, materials, and machinery in both
laboratories, but was unable to replicate the original biologic exactly.
Interview with Ralph Hall, Professor of Food & Drug Law, Univ. of Minn. Law
Sch. (Nov. 23, 2014), in Minneapolis, Minn.
34. A cell substrate is a group of cells, such as yeast or animal cells, used
to produce a certain biological product. Cell Substrates, WORLD HEALTH ORG.,
http://www.who.int/biologicals/vaccines/cell_substrates/en/ (last updated Dec.
15, 2014).
35. Id.
36. Anurag S. Rathore et al., Key Considerations for Development and
(Mar.
2,
2012),
Production
of
Vaccine
Products,
BIOPHARM
http://www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=
763581.
37. Cell Substrates, supra note 34.
38. Rathore et al., supra note 36.
39. A cell bank is storage of cells with a specific genome for future use in a
medical product. Joseph Patrick Nkolola & Thomas Hanke, Engineering Virus
Vectors for Subunit Vaccines, in NOVEL VACCINATION STRATEGIES 283 (Stefan
H. E. Kaufmann ed., 2004).
40. Rathore et al., supra note 36.
41. See AMGEN OVERVIEW, supra note 2, at 10.
42. C. Glenn Begley & Lee M. Ellis, Drug Development: Raise Standards
for Preclinical Cancer Research, 483 NATURE 531, 531–33 (2012).
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sample of innovative studies in hopes of basing future
developments off of the previous formulas, but were largely
unsuccessful in replicating the analytical studies.43 Although
this study concerned only cancer therapies, similar
shortcomings may be found in other therapies, suggesting that
significant safety concerns arise at the pre-clinical stage of
drug development. If this is the case, efforts to improve
replicability would be better spent at the earlier stages of
development as opposed to the clinical stages, as is proposed by
the extensive biosimilar approval requirements.
The FDA defines a biosimilar as a “‘biological product
[that] is highly similar to the reference product
notwithstanding minor differences in clinically inactive
components’ and that ‘there are no clinically meaningful
differences between the biological product and the reference
product in terms of the safety, purity, and potency of the
product.”44 Unsurprisingly, the definition uses ambiguous
terms and phrases, specifically, “minor differences” and
“clinically meaningful differences.” Regardless of their precise
definitions, however, these minor differences between the
original biologic and the biosimilar could pose health risks,45

43. See id.
44. FDA QUESTIONS AND ANSWERS, supra note 26, at 3 (citing 42 U.S.C. §
351(i) (2006)). Several of these terms, including “minor differences,” “clinically
inactive,” and “potency” have been discussed in the Draft Guidance, but are
still not entirely clear. The World Health Organization defines biosimilars as
“[a] biotherapeutic product which is similar in terms of quality, safety and
efficacy to an already licensed reference biotherapeutic product,” where
“similarity” is the “[a]bsence of a relevant difference in the parameter of
interest.” WORLD HEALTH ORG., GUIDELINES ON EVALUATION OF SIMILAR
BIOTHERAPEUTIC PRODUCTS (SBPS) 6 (2009), available at http://
www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_
FOR_WEB_22APRIL2010.pdf.
45. See World Health Org. [WHO], Good Manufacturing Practices for
Biological Products, at 21, WHO Doc. TRC/822 (1992), available at
http://www.who.int/biologicals/publications/trs/areas/vaccines/gmp/WHO_TRS
_822_A1.pdf (addressing the variability inherent in manufacturing biologics).
The concerns also apply to biosimilars since the same inconsistencies arise in
innovator drugs as in copycat versions. Id. Between January 1995 and June
2008, “U.S. and European regulators approved 174 biological drugs . . . . But
nearly a quarter of the biological drugs—41 out of 174—together had 82 safety
regulatory actions” after approval. Miranda Hitti, Drugs Not Without Risks:
Study Charts Safety Issues Reported After Approval of Various Biological
Drugs, WEBMD (Oct. 21, 2008), http://www.webmd.com/news/20081021/biolog
ic-drugs-not-without-risks.
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meriting a need for specific regulations for biosimilars at all
stages of its development, testing, and marketing.
B. CURRENT BIOSIMILAR LAW HAS ROOM TO GROW
While the Drug Price Competition and Patent Term
Restoration Act of 1984 (Hatch-Waxman Act)46 set a relatively
simple approval pathway for generic drugs, which are identical
to their branded counterparts,47 a parallel regulation pathway
for biosimilars would necessarily be unique and more detailed
to protect against the environmental variations that could be
consequential to the immunogenicity48 of the biosimilar.49
Hence, in 2010, the Biologics Price Competition and Innovation
Act (Biosimilars Act) was enacted as part of the Affordable
Care Act to set a standard for an abbreviated approval process
for biosimilars.50 The Biosimilars Act outlined the approval
pathway and timeline for biosimilars51 and designated the task
of implementation to the FDA.52 The FDA subsequently
released six Guidance Documents to clarify some of the
ambiguous provisions of the Biosimilars Act, add new
restrictions, and tighten the standards for some restrictions.53
46. Drug Price Competition and Patent Term Restoration (HatchWaxman) Act of 1984, 21 U.S.C. § 355(j) (2012).
47. See supra Part II.A. for a comparison of generics and biosimilar drugs.
48. Immunogenicity is the ability of a product to elicit an immune
response in the patient’s body. This is an important function in vaccines, but
the challenge is to have a balanced immune response. See Geert Leroux-Roels
et al., Vaccine Development, 1 PERSP. VACCINOLOGY 115 (2011).
49. See Addison, supra note 16, at 564–65 (“FDA spokesperson Karen
Mahoney has not . . . provided any insight as to when generic biologics may be
approved. In fact, she has stated, ‘There are so many factors that will impact
when biosimilar products will enter the market, [t]herefore, it is not
reasonable to speculate.’” (citation omitted)).
50. See FDA QUESTIONS AND ANSWERS, supra note 26, at 1–2.
51. See Public Health Service Act, 42 U.S.C. § 262(k)(1)–(2) (2012) (“Any
person may submit an application for licensure of a biological product under
this
subsection . . . . An
application . . . shall
include
information
demonstrating that . . . the biological product is biosimilar to a reference
product . . . .”).
52. Id. § 262(k)(5)(B) (“An application submitted under this subsection
shall be reviewed by the division within the Food and Drug Administration
that is responsible for the review and approval of the application under which
the reference product is licensed.”).
53. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: CLINICAL
PHARMACOLOGY DATA TO SUPPORT A DEMONSTRATION OF BIOSIMILARITY TO A
REFERENCE PRODUCT (2014) [hereinafter CLINICAL PHARMACOLOGY DATA],
available
at
http://www.fda.gov/downloads/drugs/guidancec
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Despite these attempts, both the Biosimilars Act and the FDA
Guidance Documents remain unclear on several fronts.54
For example, each time the FDA provides some direction
on how the Biosimilars Act will be interpreted,55 the
clarification disclaims that the final decision will be “made by
the FDA during its review of the 351(k) application.”56 Hence,
the FDA maintains full discretion in granting or rejecting the
application for any reason it might deem appropriate, which
means many key provisions of the Biosimilars Act and the
FDA’s interpretation remain mysterious to potential biosimilar
developers.57
The uncertainty, along with the rigorous application
requirements, is frustrating the U.S. biosimilars market; no
biosimilars are currently in the U.S. market, while several
have been developed and approved around the world.58 On

omplianceregulatoryinformation/guidances/ucm397017.pdf; U.S. FOOD &
DRUG ADMIN., GUIDANCE FOR INDUSTRY: REFERENCE PRODUCT EXCLUSIVITY
FOR BIOLOGICAL PRODUCTS FILED UNDER SECTION 351(A) OF THE PHS ACT
(2014), available at http://www.fda.gov/downloads/drugs/guidancecomp
lianceregulatoryinformation/guidances/ucm407844.pdf; U.S. FOOD & DRUG
ADMIN., GUIDANCE FOR INDUSTRY: FORMAL MEETINGS BETWEEN THE FDA
AND BIOSIMILAR BIOLOGICAL PRODUCT SPONSORS OR APPLICANTS (2013)
[hereinafter BIOSIMILAR BIOLOGICAL PRODUCT FDA MEETINGS], available at
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformatio
n/guidances/UCM345649.pdf; FDA SCIENTIFIC CONSIDERATIONS, supra note
32; U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: QUALITY
CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE
PROTEIN
PRODUCT
(2012),
available
at
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformatio
n/guidances/ucm291134.pdf; FDA QUESTIONS AND ANSWERS, supra note 26.
54. Cf. Kanter & Feldman, supra note 7, at 60–61 (making
recommendations to the current FDA policies regarding incentivizing and
implementing biosimilars).
55. FDA QUESTIONS AND ANSWERS, supra note 26.
56. See, e.g., id. at 8. “This draft guidance, when finalized, will represent
the Food and Drug Administration’s (FDA’s) current thinking on this topic. It
does not create or confer any rights for or on any person and does not operate
to bind FDA or the public. You can use an alternative approach if the
approach satisfies the requirements of the applicable statutes and
regulations.” Id. at 1.
57. Kanter & Feldman, supra note 7, at 60 (stating that the FDA and
Biosimilars Act need to offer more assurance and incentives to potential
manufacturers before they invest in the development of a biosimilar).
58. Biosimilars Approved in Europe, GENERICS & BIOSIMILARS
INITIATIVE,
http://www.gabionline.net/Biosimilars/General/Biosimilars-app
roved-in-Europe (last updated Jan. 30, 2015); see also Addison, supra note 16,
at 558–59 (describing the biosimilar approval process in Europe).
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March 6, 2015, the FDA approved Sandoz’s Zarxio, a biosimilar
referencing Amgen’s Neupogen, an expensive cancer drug, but
on May 5, 2015, the Appeals Court for the Federal Circuit
granted an injunction against Sandoz’s continued selling of
Zarxio until further notice.59 In addition, two other
biosimilars—Celltrion’s Remsima and Sandoz’s EP2006—have
applied for approval, and the Federal Circuit’s decision on
Zarxio may influence the FDA’s stance on future biosimilar
applications.60 These decisions will determine how soon the
U.S. will benefit from a robust biosimilars market.
In 2003, the European Medicines Agency (EMA) was
designated as the sole authority responsible for the oversight of
biosimilars in Europe and the approval process was effectively
centralized across all of Europe.61 The EMA released guidance
on the approval process in 2005 and the first biosimilar was
approved in 2006.62 To date, twenty-two biosimilars have been
approved in Europe; however, two approvals have been
cancelled, leaving twenty biosimilars on the current market.63
It is important to consider the reasoning behind the two
biosimilars having their approvals withdrawn in Europe.
Valtropin, made by BioPartners with the active ingredient
somatropin, was approved in April 2006 but withdrawn in May
2012 by the manufacturer itself.64 The EMA withdrew approval
59. Patience Haggin, Appeals Court Hits Pause on First US Biosimilar,
RECORDER (May 5, 2015), http://www.therecorder.com/id=1202725593394
/Federal-Circuit-Agrees-to-Block-First-US-Biosimilar?mcode=1202619176004
&curindex=3; Steven Ross Johnson, FDA Panel Recommends First Biosimilar
Approval, MODERN HEALTHCARE (Jan. 7, 2015), http://www.modernhealthcare
.com/article/20150107/NEWS/301079947.
60. See id.
61. See Biosimilars Approved in Europe, supra note 58.
62. Id. But see Addison, supra note 16, at 559 (“The year 2007 marked the
beginning of the biosimilars era in Europe.”). Hence, there is some
disagreement regarding whether 2006 or 2007 was the year that the first
biosimilar was approved in Europe.
63.For background and details on the European approval process, see Francis
Megerlin et al., Biosimilars and the European Experience: Implications for the
United States, 32 HEALTH AFF., 1803, 1804–05 (2013). For updated numbers
and a list of all approved biosimilars see European Public Assessment Reports,
EUR.
MEDICINES
AGENCY,
http://www.ema.europa.eu/ema
/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp
(follow
“browse by type” tab; then follow “biosimilars”) (last visited Apr. 4, 2015).
64. Public Statement on Valtropin (Somatropin), EUR. MEDICINES
AGENCY (May 30, 2012), http://www.ema.europa.eu/docs/en_GB/document
_library/Public_statement/2012/08/WC500130939.pdf (outlining the timeline
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upon BioPartners’ request and there is very little information
available regarding the reasons for the manufacturer’s
cessation in selling and manufacturing the drug; however,
nothing in the records indicates that it was due to safety
concerns.65 The second withdrawn biosimilar was Filgrastim
made by Ratiopharm with the active ingredient ratiopharm,
which was approved in September 2008 but withdrawn in April
2011, also at the request of the marketing authorization holder,
Ratiopharm.66 Based on the research conducted for this Note,
no indication could be found that suggested that the biosimilar
was withdrawn because it was unsafe or that the safety
concerns arose from not being able to create a biosimilar that
sufficiently mimicked the function of the original biologic.
In contrast to the centralized European system, biosimilar
approval in Latin America is nationally controlled and each
country is at a different stage of the process of developing a
regulatory system.67 The degree of regulation varies from no
regulation,68 to comprehensive and vague regulations.69 Many
Latin American countries saw the emergence of biosimilars
even before a regulatory process was developed, and several
biosimilars were simply approved under the country’s approval

of the Valtropin approval and withdrawal processes and stating only that the
withdrawal was upon the request of the manufacturer following the
manufacturer’s voluntary removal of the drug from the market).
65. See id.
66. Filgrastim Ratiopharm, EUR. MEDICINES AGENCY, http://www.ema
.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000824/hum
an_med_000792.jsp&mid=WC0b01ac058001d124 (last visited Mar. 22, 2015).
67. Compare Brian J. Malkin, Challenges to the Development of a
Biosimilars Industry in the United States, in RECENT DEVELOPMENTS IN FOOD
AND DRUG LAW 83, 83 (2013 ed. 2012) (illustrating how the western United
States and European approval processes have been centralized), with Zachary
Brennan, Uptake of Biosimilars Across Latin America Surges as Regulations
Vary, BIOPHARMA REP. (Oct. 8, 2014), http://www.biopharma-reporter
.com/Markets-Regulations/Uptake-of-biosimilars-across-Latin-America-surges
-as-regulations-vary (illustrating how the Latin American process varies
among nations, with some countries boasting an established approval system
and others still reviewing biosimilars under the generic drug model).
68. Venezuela and Chile both have biosimilars on the market but have yet
to develop a regulatory pathway specific to biosimilars. Brennan, supra note
67. Venezuela also imports biosimilars from other countries due to its lack of
production capacity, and there is little information regarding the regulations
in place for the drugs that are imported. Id.
69. For example, Mexico has a complex but vague set of regulations to
allow for case-by-case examination. Id.
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pathway for generic drugs.70 Brazil, one the first South
American countries to distinguish biosimilars from generics,
delegated the task of regulation to the National Health
Surveillance Agency (in Portuguese, Agência Nacional de
Vigilância Sanitária, ANVISA), the regulatory body for the
approval for all drugs.71 Although an estimated 187 biosimilars
are on the market in Brazil, ANVISA has not approved all of
them under the new biosimilar approval pathway and there are
no readily available records to show how many of these drugs
were approved under the generic-drug pathway.72 One possible
way for the FDA to gain information would be to study the
countries that have approved biosimilars under less restrictive
pathways, to determine whether there were inadequate levels
of similarity between the biosimilar and the original biologic.
Although no country has developed a perfect process for
the approval of biosimilars, there are some lessons the United
States can learn from the laws and approval processes
developed around the world to arrive at an appropriate
approval pathway.73 An effective biosimilar approval pathway
would necessarily need to strike a balance between ensuring
safety and providing affordable access to biologic medicines.
III. CURRENT APPROVAL PROCESS FOR BIOSIMILARS
A. CURRENT APPROVAL PROCESS FOR INNOVATOR BIOLOGICS
The Center for Biologics Evaluation and Research (CBER)
oversees the approval of original biologics.74 A biologic
70. The Future of Biosimilar Use and Regulation in Latin America,
&
BIOSIMILARS
INITIATIVE
(Aug.
29,
2014),
GENERICS
http://www.gabionline.net/layout/set/print/Biosimilars/Research/The-future-ofbiosimilar-use-and-regulation-in-Latin-America.
71. PHARM. PROD. DEV., DEVELOPING BIOSIMILARS IN EMERGING
MARKETS: REGULATORY AND CLINICAL CONSIDERATION 9–10 (2013), available
at http://www.healthtrustpg.com/biosimilars/pdf/ppd.pdf.
72. Lisa Mueller & Gustavo de Freitas Morais, Understanding Biologics
and Biosimilars in Brazil, BRIC WALL BLOG (Sept. 4, 2013),
http://bricwallblog.wordpress.com/2013/09/04/understanding-biologics-and-bio
similars-in-brazil/ (outlining the biosimilar approval process in Brazil).
73. See, e.g., supra note 71 and accompanying text.
74. The CBER gains its authority to regulate biologics from the Public
Health Service Act § 351 and specific sections of the Federal Food, Drug and
Cosmetic Act. Vaccine Product Approval Process, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biolog
icslicenseapplicationsblaprocess/ucm133096.htm (last updated June 18, 2009).
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manufacturer seeking approval for a biologic must first submit
an Investigational New Drug application (IND) to the FDA,
describing how it was manufactured, results of tests that were
conducted
for
quality,
the
biologic’s
safety
and
immunogenicity75 in animal testing, and an outline of the
proposed clinical studies the company plans to conduct if the
IND is approved.76
If permitted to proceed, the biologic undergoes at least
three phases of clinical trials.77 Phase 1 involves
immunogenicity studies performed on a small group of closely
watched individuals, while Phase 2 studies enroll hundreds of
subjects, on varying doses of the drug.78 Finally, Phase 3 trials,
for effectiveness and safety, involve thousands of subjects.79 If
clinical trials are successful, the manufacturer may file a
Biologics License Application (BLA).80 Thereafter, the FDA
reviews all submitted information, conducts a physical
inspection of the manufacturing lab during operation, and
makes a recommendation for rejection or approval of the
drug.81 However, until a biologic is on the market for some
time, it is difficult to anticipate all possible side effects.82 Thus,
Phase 4 clinical trials may be necessary to evaluate long-term
effects of a biologic.83 If any Phase raises concerns about safety

75. Immunogenicity is the “ability to elicit a protective immune response.”
Id.; see supra note 48.
76. Vaccine Product Approval Process, supra note 74.
77. Id.; see also Clinical Trials, BILL & MELINDA GATES FOUND.,
https://docs.gatesfoundation.org/documents/clinical_trials.pdf (last visited Dec.
19, 2014) (“A clinical trial is a prospective biomedical or behavioral research
study of human subjects that is designed to answer specific questions about
biomedical or behavioral interventions . . . .”).
78. Nandita Rao, FDA Q&A: The Approval Process for Vaccines and
Trumenba with Rachael Conklin: Communications Officer, PRINCETON PUB.
HEALTH REV. (Dec. 2, 2014), https://pphr.princeton.edu/2014/12/02/fda-qa-theapproval-process-for-vaccines-and-trumenba-with-rachael-conklincommunications-officer/.
79. Vaccine Product Approval Process, supra note 74.
80. Id.
81. Id.
82. Id.
83. Phase 4 clinical trials are the post-marketing surveillance trials that
are conducted through soliciting feedback from patients and health care
practitioners and facilities. See LAWRENCE M. FRIEDMAN ET AL.,
FUNDAMENTALS OF CLINICAL TRIALS 7–8 (4th ed. 2010). Phase 4 trials are also
longitudinal and help with understanding the long-term effects of the drug on
the population. Id.
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or effectiveness, the FDA can require additional studies, or halt
the process altogether.84
B. THE BIOLOGICS PRICE COMPETITION AND INNOVATION ACT
In addition to the biologic approval process, the Biologics
Price Competition and Innovation Act was added to the Public
Health Service Act (PHS Act) as section 351(k) to create an
approval pathway for biosimilars, grant exclusivity periods,
and set requirements for interchangeability.85 The Biosimilars
Act requires that a biosimilar establish its similarity to a
reference biologic through analytical data regarding its
bioequivalence,86 the results of animal studies, and clinical
studies.87 The Act also adds that the Secretary may waive any
of the requirements if it is deemed unnecessary.88 The
Biosimilars Act also establishes a twelve-year exclusivity
period for the reference product (the original biologic), during
which no biosimilar can be approved,89 and sets a four-year
exclusivity period for the reference product during which no
biosimilar can even submit an application.90
Under the Biosimilars Act, an applicant may apply for
interchangeability status either at the time it files for approval
or later.91 If a biosimilar is “interchangeable,” a pharmacist will
be allowed to substitute the biosimilar for a prescription of the
reference product without a doctor’s approval.92 To apply for
interchangeability, the applicant must additionally submit
information that the biosimilar would produce the same clinical
84. Vaccine Product Approval Process, supra note 74.
85. Public Health Service Act § 351(k), 42 U.S.C. § 262(k) (2012); see FDA
QUESTIONS AND ANSWERS, supra note 26, at 4–15. Interchangeability is the
status a biosimilar may gain in addition to being approved as a biosimilar. See
discussion infra Part IV.E.
86. Bioequivalence refers to “the relationship between two preparations of
the same drug in the same dosage form that have a similar bioavailability.”
DORLAND’S ILLUSTRATED MEDICAL DICTIONARY (William Alexander Newman
Dorland ed., 32d ed. 2011).
87. See FDA QUESTIONS AND ANSWERS, supra note 26, at 2–3; Kanter &
Feldman, supra note 7, at 71.
88. § 351(k)(2)(A)(ii).
89. This is in addition to patent protection, so many innovator drugs are
protected by both. Some may not choose to be patented, but will still have
protection for twelve years under the Biosimilars Act. § 351(k).
90. § 351(k)(7)(A)–(B); Kanter & Feldman, supra note 7, at 75.
91. § 351(k).
92. Kanter & Feldman, supra note 7, at 73.
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effects as the reference product, and that if a patient switched
back and forth between using the biosimilar and the reference
biologic, the safety and efficacy would not change.93 The first
biosimilar with interchangeability gains one year of exclusivity
over other biosimilars.94
The Biosimilars Act also provides that the “subsection (k)
applicant” must provide the “sponsor” (owner) of the reference
product with a copy of the biosimilar application, and any other
information regarding the manufacturing process for the
biosimilar.95 The reference product sponsor must keep the
information confidential but use it to give the sponsor of the
biosimilar application a list of all the ways (if any) the
applicant may be infringing on the reference product’s patents,
and identify which patents it would be willing license to the
developer of the biosimilar.96
Then, the applicant has a chance to respond to the
reference product sponsor by either agreeing with the
accusations of infringement, claiming that the patents asserted
by the reference product sponsor are invalid or not infringed by
the biosimilar, or providing a clarification that the biosimilar is
not going to be marketed before the expiration of the asserted
patents97 (biosimilar manufacturers may not be liable for
infringing a patent by making the product98). At this point, the
reference product sponsor has a chance to respond to the
biosimilar applicant, explaining why the patent(s) will be
infringed or why they are valid.99 Finally, the Biosimilars Act
provides a procedure for resolving patent disputes between

93. § 351(k)(4).
94. Id. § 351(k)(6)(A); Kanter & Feldman, supra note 7, at 73.
95. Public Health Service Act § 351(l)(2)(A), 42 U.S.C. 2(l)(2)(A) (2012).
96. Id. § 351(l)(1)(B)(iii), (3)(A)(i)–(ii).
97. Id. § 351(l)(3)(B)(i)–(ii).
98. Although a patent usually confers to its owner the right to exclude
others from making, using, or selling the patented invention, there is an
exception to this rule called the “research exception,” which states that one
will not be liable for patent infringement for performing research and tests in
preparing a product (most likely a drug) for regulatory approval, for instance
by the FDA, before the end of its patent term. Hence, developers of generic
drugs may practice the patented elements of the branded drug before the
expiration of the patent term. Gerald J. Mossinghoff, Overview of the HatchWaxman Act and its Impact on the Drug Development Process, 54 FOOD &
DRUG L.J. 187 (1999).
99. Id. § 351(l)(3)(C).
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biosimilar manufacturers and the innovator biologic
manufacturer.100
The biosimilar manufacturer is disadvantaged in the
litigation process because it might be forced to disclose trade
secrets to the reference product sponsor by sharing its
application.101 On the other hand, all elements of the reference
product may not be fully disclosed if they are not patented.102
Hence, the biosimilar manufacturer is much more exposed than
the innovator.
Although long and detailed, the Act leaves several
questions unanswered and the FDA Draft Guidance Documents
have attempted to fill in the gaps to offer clarification and
certainty.103
C. THE FDA DRAFT GUIDANCE DOCUMENTS FOR BIOSIMILARS
Since the enactment of the Biosimilars Act, the FDA has
released six Draft Guidance Documents to clarify some of the
uncertainties found in the Biosimilars Act.104 These documents
are non-binding but provide some suggestions and
recommendations for courts and the industry.105 Unlike the
EMA, the FDA has refused to set a specific guide for each type
of biosimilar and has said it is going to take a case-by-case
approach instead, deciding the level of preclinical and clinical
studies required individually for each biosimilar.106 Despite its

100. Id. § 351(l)(4)–(6); see FDA QUESTIONS AND ANSWERS, supra note 26,
at 329.
101. Kanter & Feldman, supra note 7, at 77.
102. See Addison, supra note 16, at 578.
103. FDA QUESTIONS AND ANSWERS, supra note 26; Kanter & Feldman,
supra note 7, at 71.
104. See supra note 53 (listing all six FDA Draft Guidance Documents).
105. E.g., FDA QUESTIONS AND ANSWERS, supra note 26, at 1 (“This draft
guidance, when finalized, will represent the Food and Drug Administration’s
(FDA’s) current thinking on this topic. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public.”).
106. Malkin, supra note 67, at 92 (“The FDA’s approach, moreover, puts a
high burden on would-be biosimilar applicants to develop appropriate
analytical techniques to compare their products to the referenced biological as
a prerequisite to design preclinical and clinical studies. Unfortunately, the
FDA has not specified what those analytical techniques should be. Companies
are frustrated because the agency has said it will not offer such guidance for
fear of mandating outdated technologies. According to the FDA, it wants to
provide an opportunity for biosimilar applicants to develop new analytical
methods as appropriate and feasible.”).
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attempt to clarify some of the requirements, the FDA Guidance
Documents are still ambiguous and leave many questions
unanswered.107 In addition, some aspects of the FDA
requirements are more stringent than the Biosimilars Act.108
This leaves biosimilar applicants with little direction in the
development of a biosimilar, creating high stakes and low
incentives for biosimilar developers in the United States.109
The FDA first asks the biosimilar sponsor to demonstrate
the biosimilar’s comparability to the reference product.110 A
biosimilar applicant that can demonstrate greater similarity to
the reference product will be required to conduct fewer
studies.111 The FDA also clarified that the innovator’s
comparability studies with regards to different batches of the
107. Kanter & Feldman, supra note 7, at 60 (“To combat some of the
uncertainties in the Biosimilars Act, the FDA released several draft guidances
in February 2012. These guidances provide scientific and quality
considerations in demonstrating biosimilarity. They outline the FDA’s ‘totality
of the evidence’ approach to biosimilar approval and provide a method for the
characterization of proposed biosimilars. While the Biosimilars Act and its
associated guidelines indicate that the approval process for biosimilars will be
easier and less costly than that of a pioneer biopharmaceutical drug, they
provide few clear parameters for a biosimilar manufacturer to rely on, [and]
give only a vague outline for FDA approval requirements . . . .” (footnotes
omitted)).
108. Malkin, supra note 67, at 89 (“The FDA currently views an
interchangeability determination as a two-step process. First, the FDA wants
an applicant to obtain approval for biosimilarity. Once the biosimilar has been
on the market without untoward safety or efficacy effects, the applicant can
submit additional data/information showing that it meets the
interchangeability requirements. The Biosimilars Act, however, does not
require this two-step process and permits an applicant to file its initial 351(k)
application as an interchangeable biosimilar.”).
109. Kanter & Feldman, supra note 7, at 60 (“Given the greater costs and
increased uncertainty associated with biosimilar approval, investment in the
development of such drugs will likely be inhibited, resulting in lower
availability of biosimilars and thus higher costs to consumers.”); Malkin,
supra note 67.
110. Raymond Kaiser, Why Comparability Studies Are the Key to a
Biosimilar’s Success, CONVANCE (Mar. 6, 2013), http://blog.covance
.com/2013/03/key-to-biosimilars-success/ (“In February 2012, the FDA issued
formal draft guidance on biosimilars titled ‘Scientific Considerations in
Demonstrating Biosimilarity to a Reference Product,’ in which it states that
since a one-size-fits-all pathway is not possible, it will ‘consider the totality of
evidence’ when assessing follow-on products. The cornerstone of this approach
is the structural and functional analyses of the proposed molecule
demonstrating comparability with the reference drug.”).
111. Id. (“Sponsors with compelling comparability data observe a reduced
regulatory burden.”).
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innovator biologic might not be proper guidance for comparing
the biosimilar to the innovator drug.112 The FDA additionally
requires that the biosimilar needs to be of equal strength as the
reference, and suggests that an applicant is unlikely to obtain
both biosimilarity and interchangeability through an original
351(k) application.113 The FDA also iterates its hesitance in
allowing comparability studies from other countries, but does
not give a reason for this exclusion.114
Following a showing of analytical and physical
comparability,115 the FDA approval pathway starts with the
applicant conducting in vitro studies to show similarity of the
physiological properties of the drug, followed by animal testing
for toxicity.116 The final stage is in vivo clinical studies.117
According to the Biosimilars Act, the Secretary has the
discretion to waive any stage of the testing requirements.118
One of the most important questions for biosimilar developers
will be how likely the FDA will be to require clinical studies—
the most costly and time-consuming stage of the approval
pathway.119 Another key question will be the requirements and
process of gaining interchangeability of biosimilars.

112. Malkin, supra note 67, at 96 (“The FDA has said that while an
innovator’s comparability studies may be useful as goalposts for biosimilars,
they may not apply to or be practical when developing a biosimilar product.”).
113. FDA QUESTIONS AND ANSWERS, supra note 26, at 10 (“Under section
351(k)(2)(A)(i)(IV) of the PHS Act, an applicant must demonstrate that the
‘strength’ of the proposed biosimilar product is the same as that of the
reference product.”).
114. See id. at 7–8.
115. Comparability needs to show that the primary, secondary, tertiary,
and quaternary structures are the same as the innovator product, that the
biological activity is sufficiently similar, and that there are negligible product
and process impurities. This analysis is done through various advanced
technologies including mass spectrometry, NMR, and other measures. Kaiser,
supra note 110.
116. Malkin, supra note 67, at 96 (“For example, at the beginning of the
product development process, the first tests are in vitro, followed by some
animal testing to prove that the drug is not toxic.”).
117. Id. (“Next, smaller clinical studies are conducted in vivo to determine
whether the drug has some beneficial effect, followed by a study to determine
the optimal dosing strategy.”).
118. See Public Health Service Act, 42 U.S.C. § 262(k)(2)(A)(ii) (2012).
119. CLINICAL TRIALS OF DRUGS AND BIOPHARMACEUTICALS 1–2 (Chi-Jen
Lee et al. eds., 2005) (discussing the factors that determine whether clinical
studies are required for biopharmaceuticals).
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One helpful guide provided by the FDA is its attempt to
clarify the ways in which a biosimilar applicant can
demonstrate similarity to the reference product. The FDA
encourages the applicant to submit information about how the
biosimilar compares to the reference product with regards to
“structure, function, animal toxicity, human pharmacokinetics
(PK) and pharmacodynamics (PD), clinical immunogenicity,
and clinical safety and effectiveness.”120 The guidance lists
some of the specific impurities and inconsistencies may appear
in the biosimilar manufacturing process as well as how these
impurities appear.121 The Guidance Document proceeds to list
technologies and methods that may, and should, be employed
to detect these inconsistencies between products.122 In essence,
however, the FDA Guidance Document says little more than
what is already in the Biosimilars Act.123 In fact, it re-affirms
that the default expectation is that a biosimilar application will
contain analytical studies, animal studies, and clinical studies,
unless otherwise specified by an FDA official.124 The general
impression given by the Guidance Documents is that at least
one clinical study will be required.125 For example, the
guidance clearly states, “Animal PK and PD assessment will

120. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 2. PK refers to
the body’s absorption, distribution, metabolism, and elimination of a drug. Id.
at 13 n.25. PD refers to the biochemical and physiologic effects the drug has on
the body. Id.
121. Id. at 5 (“In general, proteins can differ in at least three ways: (1)
primary amino acid sequence; (2) modification to amino acids, such as sugar
moieties (glycosylation) or other side chains; and (3) higher order structure
(protein folding and protein-protein interactions).”).
122. Id.
123. See Kanter & Feldman, supra note 7, at 71–73.
124. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 4 (“An
application submitted under section 351(k) of the PHS Act must contain,
among other things, information demonstrating that ‘the biological product is
biosimilar to a reference product’ based upon data derived from: Analytical
studies that demonstrate that the biological product is highly similar to the
reference product notwithstanding minor differences in clinically inactive
components; Animal studies (including the assessment of toxicity); and A
clinical study or studies (including the assessment of immunogenicity and
pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate
safety, purity, and potency in one or more appropriate conditions of use for
which the reference product is licensed and intended to be used and for which
licensure is sought for the biological product.” (citation omitted)).
125. See generally id.
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not negate the need for human PK and PD studies.”126 This
does little more than to reiterate the provisions of the
Biosimilars Act. Hence, the uncertainty of Biosimilars Act
remains, and it places a disproportionate amount of discretion
in the FDA approval process.127
Another way the FDA attempts to resolve the uncertainty
is by stating that it will have up to five formal meetings with
each prospective biosimilar applicant throughout the
development and testing process to provide the applicant with
feedback.128 The first meeting involves the applicant providing
“preliminary comparative analytical similarity data” so the
FDA may assess whether the biosimilar approval is feasible.129
The last of the five meetings assist the applicant in preparing a
“section 351(k)” application to file.130 This process will
supposedly give the applicant a better idea of how much
investment will be required for the application process before it
begins.
The FDA further relaxes the requirements by suggesting
that biosimilars do not need to have exactly the same
“formulation” or production method as the reference biologic
and may be enclosed in a different container or delivery
device.131 Also, biosimilars may obtain approval for only some
of the elements embodied in the reference product.132 For
example, the applicant may only want to obtain biosimilarity
status for the strength or container of the reference product.133
The FDA also notes that biosimilar applicants could use
comparative studies from the non-U.S.-licensed product to

3.

126. Id. at 13.
127. See id. at 4, 13.
128. BIOSIMILAR BIOLOGICAL PRODUCT FDA MEETINGS, supra note 53, at

129. Id.
130. Id. at 4.
131. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 8 (“A sponsor
may be able to demonstrate biosimilarity even though there are formulation or
minor structural differences, provided that the sponsor provides sufficient
data and information demonstrating that the differences are not clinically
meaningful and the proposed product otherwise meets the statutory criteria
for biosimilarity.”).
132. Id. at 5 (“Thus, as set forth in the PHS Act, data derived from
analytical studies, animal studies, and a clinical study or studies are required
to demonstrate biosimilarity unless FDA determines an element
unnecessary.”).
133. See FDA QUESTIONS AND ANSWERS, supra note 26, at 5–6.
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demonstrate a biosimilar’s equivalency to a reference biologic,
specifically for animal and clinical studies.134 However, the
original reference product needs to have been approved in the
United States and the FDA has a long list of eligibility
requirements before an applicant may reference a foreignlicensed product.135 In addition, clinical comparisons with a
non-U.S.-licensed product would likely not support a finding of
interchangeability, even if approval were granted.136 Also, an
applicant may extrapolate clinical data of biosimilarity from
one condition to another condition for which the reference
product is licensed.137
Despite these attempts to clarify the process, many
uncertainties in the approval pathway remain. The FDA
Guidance Documents are nonbinding and have only been
implemented in the approval of one biosimilar so far.
Furthermore, most sections of the FDA Draft Guidance
Documents disclaim that the ultimate decision will be left to
the official at the time of approval.138
IV. PROPOSED REVISIONS AND RECOMMENDATIONS TO
THE BIOSIMILAR DEVELOPMENT AND APPROVAL
PROCESS
The primary challenge with developing an effective
approval process for biosimilars is finding a happy balance
between ensuring safety and efficacy while improving access
and
incentivizing
research,
development,
and
fair

134. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 6 (“However,
under certain circumstances, a sponsor may seek to use data derived from
animal or clinical studies comparing a proposed product with a non-U.S.licensed product to address, in part, the requirements under section
351(k)(2)(A) of the PHS Act. In such a case, the sponsor should provide
adequate data or information to scientifically justify the relevance of this
comparative data to an assessment of biosimilarity and to establish an
acceptable bridge to the U.S.-licensed reference product.” (citation omitted)).
See argument, infra Part IV., for a discussion regarding using other countries’
data on biosimilarity and suggestions for extrapolating that data for use in
U.S. approval systems.
135. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 6 (citing FDA
QUESTIONS AND ANSWERS, supra note 26, at 7–8).
136. Id.
137. Id. at 19–20.
138. See FDA QUESTIONS AND ANSWERS, supra note 26, at 2–3.
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competition.139 At the moment, however, the scale tips strongly
against biosimilars.140 The reasons for this are not necessarily
safety and efficacy concerns, but rather political lobbying and
interests of current industry players.141 Innovator biologics and
their beneficiaries are pushing for more stringent requirements
for biosimilar approval in order to protect their own market
interests and limit competition.142 On the other hand, many
scientists, lawyers, and governmental agencies have expressed
the view that the current approval process is unnecessarily
rigorous for biosimilar applicants and is discouraging research
and
limiting
access
to
important
large
molecule
pharmaceuticals.143 This view has gained several supporters in
the last few years, especially in light of the fact that not a
single biosimilar has entered the market in the United States
since the enactment of the Biosimilars Act in 2010, while
several biosimilars have been safely introduced into foreign
markets.144
Although several companies have filed biosimilar
applications, including Celltrion’s outstanding application for a

139. See Economic Impact Analyses of FDA Regulations, supra note 18
(discussing the FDA’s cost-benefit analysis in approving and regulating
drugs).
140. Kanter & Feldman, supra note 7, at 69 (“While the framework set
forth by the Biosimilars Act and the FDA’s recent draft guidances is certainly
better than no framework at all, the incentives provided for biosimilar
development are less robust than incentives for generic production under the
Hatch-Waxman Act, and are unlikely to be sufficient to attract much activity
in the biosimilars market.”).
141. See Timothy J. Shea, Jr., Director, Sterne, Kessler, Goldstein & Fox
P.L.L.C., Presentation at the BIO International Conference, The New
Biosimilars Act: Overview of the Legislation and IP Implications (Mar. 4,
2011), available at http://www.skgf.com/themes/default/public/media/pnc/9
/media.1299.pdf (discussing the political climate in the industry on pages 3–5).
142. Groups such as the Pharmaceutical Research and Manufacturers of
America (PhRMA) and the Biotechnology Industry Organization fought
fiercely to increase the number of years of exclusivity for innovator biologics.
See e.g., Donna Young, Obama Reignites 7-Year Biosimilar Exclusion and
Inflames “Innovators”, PHARMASHARE (Apr. 10, 2011), http://www.pharma-sh
are.com/obama-reignites-7-year-biosimilar-exclusion-inflames-innovators.
143. See id.
144. See Kanter & Feldman, supra note 7, at 78; Haggin, supra note 59;
Lisa Mueller, A Review of the Status of Biosimilars in the U.S., BRIC WALL
BLOG (Oct. 27, 2014), http://bricwallblog.wordpress.com/2014/10/27/a-reviewof-the-status-of-biosimilars-in-the-u-s/.

2015]

BIOSIMILAR REGULATION

903

biosimilar version of infliximab,145 several revisions will need to
be made not only to the Biosimilars Act, but also to the FDA’s
implementation of the Act, and to the overall understanding of
biosimilars among health care professionals and the general
public if we are to truly realize the benefits of biosimilars.146
One approach to changing the state of the biosimilar laws
in the United States is to look to the approval pathways of
other countries such as those in Europe, Asia, and Latin
America to see which strategies have worked in those
countries. Other approaches involve engaging with domestic
health care practitioners, policy makers, and the general public
to understand the unique needs of the U.S. pharmaceutical
market.
A. INNOVATOR BIOLOGICS SHOULD BE GRANTED LESS
EXCLUSIVITY
One of the main deterrents for the development of
biosimilars is the twelve-year exclusivity period for innovator
biologics, which has repeatedly been characterized as excessive
by bodies such as the Generic Pharmaceutical Association
(GPhA), the Federal Trade Commission, and President
Obama.147 Those holding this belief assert that the requirement
should be around five to seven years as for small molecule
chemical drugs.148 Estimates from the White House contend
that this measure could save as much as $2.34 billion in health
145. Mueller, supra note 144. Remicade is the commercial name for
infliximab in many countries. Id.
146. Id.
147. Kanter & Feldman, supra note 7, at 75, 80. The FTC stated that the
twelve-year exclusivity period is “unnecessary to promote innovation by brand
biologic drug manufacturers and can potentially harm consumers by directing
scarce research and development funding toward developing low-risk clinical
data for drug products with proven mechanisms of action rather than toward
new products to address unmet medical needs.” OFFICE OF MGMT. & BUDGET,
EXEC. OFFICE OF THE PRESIDENT, TERMINATIONS, REDUCTIONS, AND SAVINGS:
BUDGET OF THE U.S. GOVERNMENT, FISCAL YEAR 2012, at 119 (2011) (footnote
omitted),
available
at
http://www.whitehouse.gov/sites/default/
files/omb/budget/fy2012/assets/trs.pdf.
148. Malkin, supra note 67, at 88 (“Biological innovators want more time,
while biosimilar applicants, many legislators, and even President Barack
Obama, want this exclusivity period to be closer to the five-year new-chemicalentity exclusivity period for small molecules.”); Young, supra note 142 (“In his
$3.73 trillion fiscal year 2012 budget announced 14 February is a proposal
that seeks to reduce from 12 to seven the years of data exclusivity protection
for “innovator” biologics against follow-on biologics.”).
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care costs over ten years.149 In addition, innovative biologic
developers would still recover the costs of developing a novel
drug under the reduced exclusivity period and patents,
allowing for double protection, would also cover many drugs.150
Arriving at an effective exclusivity term involves balancing the
desire to provide incentives for innovators while encouraging
the creation of copycat drugs that lower the cost of necessary
treatment for Americans.
One country that follows an extreme version of this
proposal is Brazil. Brazil’s recently enacted biosimilar law does
not grant any period of exclusivity to the original biologic
developer.151 Therefore, there is no data exclusivity period for
new biological products and a generic or biosimilar could be
registered any time after a new small molecule drug or biologic
has been approved.152
Alternatively, Congress could enact a separate, shorter
patent term only for biologics, or a provision that states that
the only exclusivity available to innovator biologics would be
the twelve years afforded by the Biosimilars Act and FDA
Guidance Documents.153 In Europe, although the patent term is
also twenty years, many biologic patents are expected to expire
much earlier than in the United States and more biosimilars
have been developed.154 For example, Ovaleap, a follitropin alfa
biosimilar made by Teva Pharmaceutical Industries was
approved in the European Union in September 2013.155 The

149. Young, supra note 142 (stating that this is “an argument the
President had made during the formulation of the health reform law last year,
but which had been rejected”).
150. See id.
151. Mueller & de Freitas Morais, supra note 72 (“Brazilian law does not
provide any regulatory/data exclusivity periods for new pharmaceuticals
(small molecules) or new biological products (biologics) for human use.”).
152. Id. (“Thus, in practice, ANVISA will register any generic drug (such as
a branded or non-branded small molecule) or biological product (biosimilar) for
human use any time after the registration of a new drug or new biological
product (biologic).”).
153. See supra note 89 and accompanying text.
154. See Leigh Anderson, Biosimilars in 2015 – What Can We Expect?,
DRUGS.COM (Jan. 2015), http://www.drugs.com/news/biosimilars-2015-can-weexpect-55159.html.
155. EMA Approves Biosimilar Follitropin Alfa and Somatropin, GENERICS
& BIOSIMILARS INITIATIVE (Sept. 20, 2013), http://www.gabionline.net/Biosim
ilars/News/EMA-approves-biosimilar-follitropin-alfa-and-somatropin (“[O]n 9
September 2013, the [European Medicines Agency] announced the approval of
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European patents for the original follitropin alfa, Gonal-F,
expired in 2009, whereas the U.S. patents expire in 2015.156 A
shorter duration in patent term will counter the delay in
follow-on biologics (including biosimilars and biobetters157)
entering the market, and expedite the availability of the drug
to the population in the same way that limiting the Biosimilars
Act exclusivity would. Patent terms are longer than twelve
years, which will mean drugs protected only by the Biosimilars
Act will be able to be copied much earlier.
However, patents are uncertain and require a showing of
several other elements such as novelty and non-obviousness,
which means that biosimilarity exclusivity is more likely to be
granted than patent protection.158 This will provide more
certainty for biologics, but also limit the exclusivity of a drug if
only one provision is providing it with exclusivity instead of
two. In addition, patents require that the product information
be publicly disclosed for all the elements of the product, which
assists biosimilar developers in making comparable
products.159 This is a great benefit for the follow-on biologic and
limiting it will affect developers’ ability to make comparable
biosimilars, which is a primary factor in their approval
decision.160 One way to resolve this issue would be to require
that the original biologic manufacturer disclose the elements of
their product at the end of the twelve-year exclusivity period.
Under this structure, the exclusivity will provide a full twelve
years before any biosimilar can be approved, during which time

a new somatropin biosimilar. The follitropin alfa biosimilar (Ovaleap) is
produced by generics giant Teva Pharmaceutical Industries.”).
156. Biosimilars Applications Under Review by EMA – 2013 Q4, GENERICS
& BIOSIMILARS INITIATIVE (Jan. 17, 2014), http://gabionline.net/Biosimilars
/General/Biosimilars-applications-under-review-by-EMA-2013-Q4.
157. Unlike biosimilars, biobetters are “improved” versions of the original
biologic, although they are in the same family as the biologic. Biobetters may
qualify for their own patent and the FDA twelve-year protection. Fiona Barry,
Generation of Biobetters Could Push Out Biosimilar Development, Says
Expert, BIOPHARMA (Apr. 23, 2014), http://www.biopharma-reporter.com/BioDevelopments/Generation-of-biobetters-could-push-out-biosimilar-developmen
t-says-expert.
158. See America Invents Act, 35 U.S.C. §§ 102–103 (2012).
159. Id. § 102.
FOOD
&
DRUG
ADMIN.,
160. Biosimilars,
U.S.
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredeveloped
andapproved/approvalapplications/therapeuticbiologicapplications/biosimilars
/default.htm (last updated Mar. 6, 2015).
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biosimilar manufacturers will be free to reverse-engineer the
original product, as is the case currently. After the twelve-year
period, however, the information will be disclosed to help
future biosimilar developers to make the product a more
accurate copy of the original.
B. APPROVAL SHOULD REQUIRE FEWER STUDIES
Another way to incentivize biosimilars is by limiting the
number of tests and studies for the application process, and
finding other ways for the biosimilar applicant to demonstrate
biosimilarity, safety, and efficacy. This can be done in several
ways, especially given the numerous technological advances
that allow for accurate characterization of proteins and
chemical molecules. Deciding on an optimum number of studies
required to ensure safety and efficacy while maintaining
incentives for drug developers poses a careful balancing act for
the FDA.
First, the FDA could require fewer studies if the biosimilar
has been approved in different countries. For example, if the
biosimilar manufacturer has been approved to produce the
same biosimilar in a foreign country, the FDA could allow—to a
greater degree than is presently accepted—the results of
analytical studies, animal studies and clinical studies from that
approval process to be used in the application in the United
States. Currently, the FDA has said that foreign animal and
clinical studies may be accepted, but must show a sufficient
connection to the biologic reference product approved in the
United States through bridging studies between the biosimilar
and the U.S.-licensed reference product.161 In an FDA guidance
document regarding the acceptability of foreign clinical data
used for small molecule drugs, the FDA cites to the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH)162 for an idea of how bridge studies may be
conducted.163 Some of the factors the FDA considers in
161. FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 6.
162. ICH is an international platform that brings together regulatory
pharmaceutical bodies from around the world to discuss drug registration and
compliance. ICH, http://www.ich.org/ (last visited Mar. 17, 2014).
163. FDA GUIDANCE FOR INDUSTRY: E5 – ETHNIC FACTORS IN THE
ACCEPTABILITY OF FOREIGN CLINICAL DATA 2 (2006), available at
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073120.pdf (“[I]f the
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assuming a sufficient bridge between the biosimilar and the
U.S.-licensed biologic include the design of the overseas clinical
study, the manufacturers of the biosimilar and reference
product, and the standards that were followed in obtaining
approval for the biosimilar overseas.164
The more thoroughly a biosimilar applicant addresses
these issues, the more likely the foreign studies are to be
sufficient. However, the FDA still maintains that the
requirements are “not limited to” these criteria, creating
uncertainty for the applicant.165 In addition, although the FDA
states factors it will consider, it does not state how these
factors will affect the decision and to what extent each factor
matters.166 The FDA also fails to answer important questions
such as whether the clinical studies have to be at a certain dose
or strength in order to fulfill the requirements.167 Although
there are countless little details that no guidance can cover, it
would be helpful for the FDA to give a list of examples of the
kinds of clinical and animal studies that would be acceptable.
These examples would make up for the lack of history in
biosimilar approval.
In addition, if there are already several biosimilar drugs on
the market that copy the same reference product, and if the
applicant’s biosimilar has a structure and function within the
range of drugs on the market that have been proven to be
effective and safe, the FDA could lower the requirements since
previous applicants have already tested similar processes and
proven them to be safe. As the number of biosimilars copying a
single reference product increases, there will be less
uncertainty in the effects of minor changes to its structure,
genetic make-up, container, and other variables. Therefore, the
second biosimilar application should be viewed less stringently
than the first, and the third should be approved more readily

data developed in one region satisfy the requirements for evidence in a new
region, but there is a concern about possible intrinsic or extrinsic ethnic
differences between the two regions, then it should be possible to extrapolate
the data to the new region with a single bridging study. The bridging study
could be a pharmacodynamic study or a full clinical trial, possibly a doseresponse study.”).
164. FDA QUESTIONS AND ANSWERS, supra note 26, at 7–14.
165. See FDA SCIENTIFIC CONSIDERATIONS, supra note 32, at 10.
166. Id. at 16–17.
167. Id. at 17–20.
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than the second, given that there are only negligible changes in
the manufacturing process and final product.
C. TESTING SHOULD INCREASE AT EARLIER STAGES OF
DEVELOPMENT
Another way to reduce the burden on biosimilar developers
is to rely heavily on technological advances that allow for
accurate imaging and characterization of a biosimilar. There
are many instruments and scientific methods that make it
possible for a researcher to view the amino acid and protein
structures, modifications, and minor impurities.168 Although
these methods are not perfect, they can provide a strong sense
of a biosimilar’s likeness to an innovator biologic.169 Although
some of the instruments are expensive, this method of testing
biosimilars is still cheaper than clinical studies, so more time
and resources should be invested in conducting careful visual,
chemical, and biological analysis to determine the structural
biosimilarity of the drug.170 Both the drug developer and the
FDA testing office can perform these tests and many such tests
are already in use.171 When combined with reasonable policies
and regulations, these technological measures can reduce the
inconsistencies that exist in biologic and biosimilar
development.172
First, a pharmaceutical company already must comply
with the FDA’s Current Good Manufacturing Practices
(CGMPs).173 These practices ensure that a manufacturer uses
“proper design, monitoring, and control of [the] manufacturing

168. See, e.g., Yi Qun Xiao, Meeting the Challenges of Biosimilars, MPI
RES. (June 12, 2014), http://www.mpiresearch.com/meeting-challengesbiosimilars/ (discussing a pharmacokinetics assay and a technique that
combines two assay results to overcome the challenges of biosimilar
development).
169. Id.
170. See generally Leili Fatehi et al., Recommendations for Nanomedicine
Human Subjects Research Oversight: An Evolutionary Approach for an
Emerging Field, 40 J.L. MED. & ETHICS 716, 723 (2012) (discussing, generally,
the costs of trials on human subjects).
171. See CLINICAL PHARMACOLOGY DATA, supra note 53, at 4–6; FDA
SCIENTIFIC CONSIDERATIONS, supra note 32, at 8–10.
172. Rathore et al., supra note 36.
173. Facts About the Current Good Manufacturing Practices (CGMPs), U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DevelopmentApproval
Process/Manufacturing/ucm169105.htm (last updated Jan. 6, 2015).
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processes and facilities.”174 Following these practices “assures
the identity, strength, quality, and purity of drug products,” by
requiring “strong quality management systems, obtaining
appropriate quality raw materials, establishing robust
operating procedures, detecting and investigating product
quality deviations, and maintaining reliable testing
laboratories.”175 This is only the first step of many checkpoints
that ensure that the final product is safe.176
Second, there are many ways to observe and characterize
the biological products at the microscopic level, which can
provide information about their similarity to the innovator and
detect potential inconsistencies. Two of these advanced
techniques of characterizing molecules are light scattering177
and nuclear magnetic resonance (NMR) spectroscopy.178
Through these techniques, each intermediate product of the
process can be closely characterized to create continuous cell
lines for consistent same cell substrates, and see the folding
patterns and added side chains in the final molecule.179
There have been very few (if any) cases of biosimilars being
dangerous because they were inaccurately copied from the
innovator. In addition, although some branded biologics have
been removed from the market, it has seldom been due to the
inconsistency between batches.180 In the past, the FDA has
required batch certification for antibiotics, which requires the
manufacturer to send samples for batch-specific testing even
after the drug was approved.181 However, as technology and

174. Id.
175. Id.
176. See id.; Daron I. Freedberg, Improvement of Biological Product
Quality by Application of New Technologies to Characterize of Vaccines and
Blood Products: NMR Spectroscopy and Light Scattering, U.S. FOOD & DRUG
ADMIN.,
http://www.fda.gov/biologicsbloodvaccines/scienceresearch/biologics
researchareas/ucm127270.htm (last updated Feb. 13, 2015).
177. Light scattering identifies molecular weight and size by examining the
reflection of light off the molecule. Freedberg, supra note 176; see CRAIG F.
BOHREN & DONALD R. HUFFMAN, ABSORPTION AND SCATTERING OF LIGHT BY
SMALL PARTICLES 3–11 (1983).
178. NMR uses magnetic fields and radio waves to form images of organic
molecules. L.G. WADE, JR., ORGANIC CHEMISTRY 559–61 (6th ed. 2006).
179. See Cell Substrates, supra note 34.
180. See infra note 182 and accompanying text.
181. Regulatory Information: FDA Backgrounder on FDAMA, U.S. FOOD &
DRUG ADMIN. (Nov. 21, 1997), http://www.fda.gov/regulatoryinformation/legis
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regulation improved, there was less need for the intermittent
testing and by 1981, less than one percent of batches were
rejected from safety issues arising during the batch tests.182
Although the batch certification requirement has since been
abolished,183 there are new areas of safety to focus on.
As Glenn Begley and Lee Ellis’s findings suggest, at least a
significant part of the issue lies at the initial stages of the
development process because the in vitro analytical data were
not able to be replicated easily,184 suggesting we need to work
on increasing the replicability of data from the analytical
stages, because that will lead to better in vivo results
downstream.185 Another challenge is finding anti-biosimilar
antibodies for immunogenicity assays, which are not as readily
available as for the biologic.186 One solution is to use two assays
composed of both the innovator and biosimilar as attaching and
detecting agents, and then compare the two assays for drug
tolerance, sensitivity, and specificity in the enzyme-linked
immunosorbent assays.187 Through adopting these and other
measures, the biosimilar manufacturers and FDA testing
agency can ensure comparability of the biosimilar at the
analytical stage and require fewer clinical and animal studies.
In addition to being cost-prohibitive and time-consuming,
clinical studies are not as useful as they are often purported to
be, since clinical studies are usually performed on healthy

lation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact
/fdama/ucm089179.htm.
182. U.S. GEN. ACCOUNTING OFFICE, FDA SHOULD REDUCE EXPENSIVE
ANTIBIOTIC TESTING AND CHARGE FEES WHICH MORE CLOSELY REFLECT COST
OF CERTIFICATION 8 (1981), available at http://www.gao.gov/assets
/140/135632.pdf (“The rejection rates for antibiotic batches has traditionally
been low. Since 1948, the annual rejection rate has not exceeded 1.2 percent
and has been as low as 0.13 percent.”).
183. Richard Rowberg et al., Food and Drug Administration Modernization
Act of 1997 – The Provisions, in THE FOOD AND DRUG ADMINISTRATION (FDA)
63, 79 (Meredith A. Hickmann ed., 2003).
184. See supra Part II.A.
185. Their study suggests that the analytical stages of the biologic’s
development are the most vulnerable to replicability problems. Begley & Ellis,
supra note 42. See supra Part II.A.
186. Enzyme-linked immunosorbent assays require antigens that will bind
to the biosimilars. Michele Kessler et al., Immunogenicity of
Biopharmaceuticals, 21 NEPHROLOGY DIALYSIS TRANSPLANTATION 9, 9–11
(2006).
187. Xiao, supra note 168.
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subjects who are not representative of the population that will
be using the drug.188
Furthermore, none of the already-approved biosimilars
have been found to have serious negative health effects.189 This
indicates that post-grant recall for safety is not a major
concern. Ortwin Renn conceptualizes risk with an integrative
approach considering the technical, social, cultural, and
economic aspects of the harm, as well as the magnitude of the
harm.190 He also states, “society is not only concerned about
risk minimization. People are willing to suffer harm if they feel
it is justified or if it serves other goals.”191 Hence, although
pharmaceuticals may never be risk free, a logical balance may
be struck between the safety, efficacy, cost, and accessibility of
biosimilars.
D. PHARMACISTS AND DOCTORS MUST BE IN THE LOOP
Any biosimilars reform necessarily needs to involve health
care practitioners, such as doctors, nurses, and pharmacists,
not only to be able to control the distribution of biosimilars, but
also to spread the word to the public about their risks, benefits,
and regulatory schemes. At the moment, few people are aware
of the existence of biosimilars, particularly in the United
States, and even fewer have a basic understanding of the
concepts behind them. If doctors are well informed about the
risks and benefits, they will be more or equally likely to
prescribe the biosimilar as compared to the innovator biologic,
providing manufacturers incentives to develop biosimilars even
without interchangeability.
Pharmacists can also be educated to make effective and
safe biosimilar substitutions and they may be given more say
in the substitution decision.192 The FDA should plan to educate
pharmacists about the available biosimilars and how they are

188. See The Utility of Clinical Trials for Biosimilars, GPHA,
http://www.gphaonline.org/gpha-media/gpha-resources/the-utility-of-clinical-tr
ials-for-biosimilars (last visited Mar. 7, 2015).
189. See supra notes 63–66 and accompanying text.
190. Ortwin Renn, Concepts of Risk: A Classification, in SOCIAL THEORIES
OF RISK 53, 77 (Sheldon Krimsky & Dominic Golding eds., 1992).
191. Id.
192. Malkin, supra note 67, at 90.

912

MINN. J.L. SCI. & TECH.

[Vol. 16:2

different (if material) from the biologic.193 Congress should
enact laws that allow pharmacists to make informed decisions
regarding the substitution of a biosimilar.194 One way to enable
pharmacists to make substitutions would be to require that all
biosimilars are “labeled with . . . International Nonproprietary
Names (INNs), using individual National Drug Codes (NDCs)”
so pharmacists can easily identify and distinguish reference
biologics and their biosimilars and make educated decisions in
substituting them.195
E. TWO ALTERNATIVES TO THE INTERCHANGEABILITY
PROCEDURE
The other way to make biosimilars a more proximate
reality is to reform the law around interchangeability.
Presently, to gain interchangeability, the biosimilar
manufacturer needs to prove that the biosimilar has the “same
clinical result in any given patient as the referenced product. In
addition, for biological products that are administered more
than once, the biosimilar product would produce the same
clinical result when switching from the referenced product to
the biosimilar and back again.”196 But switching between the
products need not be an integral part of the interchangeability
status. With diligent recordkeeping, a patient can be kept on
one biologic or biosimilar and not have to switch back and
forth.
There are two ways the FDA could alter this standard.
First, the FDA could maintain a rigorous approval process for
biosimilars but grant interchangeability to all approved
biosimilars. The approval requirements for biosimilars would
193. Id. (discussing how pharmacists want the FDA’s help in such
education and how “they want the FDA to opine on when pharmacists can
substitute biosimilar products without a physician’s consent”).
194. Id.
195. Id. at 67–68. The INNs for biologics are decided by a committee such
that the names are standardized and easy to understand around the world.
WORLD HEALTH ORG., WHO INFORMAL CONSULTATION ON INTERNATIONAL
NONPROPRIETARY NAMES (INN) POLICY FOR BIOSIMILAR PRODUCTS 4–5
(2006), available at http://www.who.int/medicines/services/inn/BiosimilarsI
NN_Report.pdf. While the FDA is hesitant to use this approach for biosimilars
as well, the WHO guidelines on naming suggest that the same naming
approach be taken for biosimilars as is taken for innovator biologics. Id. at 11–
12 (providing the recommendations proposed for the biosimilars naming
process).
196. Malkin, supra note 67, at 89.
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need to be more rigid to ensure safe substitution of prescribed
biologics. This could be achieved in several ways, including
requiring a greater number of studies to show comparability,
safety and efficacy. One risk with automatic substitution is not
being able to trace the cause in case of an adverse drug
reaction.197 If biosimilars are automatically interchanged,
records might be less thorough, especially if a patient switches
back and forth between the original biologic and many other
biosimilars. However, as mentioned in the previous paragraph,
this could be corrected for with extensive recordkeeping and
not having patients take different biosimilars that are based on
the same biologic. One more concern of easily granted
interchangeability “is the possibility that repeated switches
between the biosimilar and the reference product may increase
immunogenicity with potentially negative effects on the safety
and/or efficacy of the products.”198 Automatic substitution has
not yet been accepted in the European Union, and “more than
12 countries across Europe have introduced rules to prevent
automatic
substitution
of
biological
medicines
by
biosimilars.”199
Alternatively, the FDA could continue to treat
interchangeability as a separate question, requiring a separate
application, but lower the standards for obtaining biosimilar
status. This way, either the approval pathway for biosimilars is
made easier and interchangeability is only granted after a drug
has proven itself on the market, or the pathway is similarly
maintained in its current burdensome state but the biosimilar
is deemed interchangeable as soon as it is approved as a
biosimilar. Either way, under this second alternative, the
biosimilar approval process would be much less rigorous,
reducing the number of studies required. Of course, the glaring
concern with this approach is that biosimilars will be
interchangeable with less scrutiny, which may lead to unsafe
197. Martina Weise et al., Biosimilars: What Clinicians Should Know, 120
BLOOD J. 5111, 5114 (2012).
198. Id.
199. Efficacy, Extrapolation and Interchangeability of Biosimilars,
&
BIOSIMILARS
INITIATIVE
(Apr.
19,
2013),
GENERICS
http://www.gabionline.net/Biosimilars/Research/Efficacy-extrapolation-and-int
erchangeability-of-biosimilars; see also Frequently Asked Questions About
GENERIC
MEDICINES
ASS’N,
Biosimilar
Medicines,
EUR.
http://www.egagenerics.com/index.php/biosimilar-medicines/faq-on-biosimilars
(last visited Apr. 6, 2015).
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results. To resolve this issue, the FDA should take several
actions.
First, the biosimilar applicant should be required to make
public all the information about the product, including the
risks, the differences from the innovator biologic, whether it
has been approved in other countries, and any potential side
effects observed in animal or local studies. With this
information readily available, doctors, pharmacists, and
patients will be able to make educated decisions about
prescribing and using the biosimilar. Such an approach is
implemented in the overall health care system in Singapore
and could provide useful reference for other countries.200 The
FDA could mandate that the biosimilar applicant release
analytical information about the drug, the number of empirical
studies conducted, the results of any animal or clinical tests,
and names of other similar drugs.201 In addition, patients could
be required to sign a waiver that indicates that they have read
the relevant information and understand the risks and
benefits. This would shift part of the burden of the decision to
the patient, ensuring that patients are taking measures to
educate themselves about the risks and benefits, instead of
simply buying the cheapest drug and assuming it is equally
effective and safe.
Currently, interchangeability is one of the main incentives
for biosimilar developers because it greatly increases the
profitability of a biosimilar.202 The FDA presently requires the
200. WILLIAM A. HASELTINE, AFFORDABLE EXCELLENCE: THE SINGAPORE
HEALTHCARE STORY 14–15 (2013) (discussing the practices of one of the
world’s best medical systems, and the role different groups—including doctors,
regulatory officials, and patients play in the system to keep it alive).
201. Karen Feldscher, Singapore’s Health Care System Holds Valuable
Lessons for U.S., HARV. SCHOOL PUB. HEALTH NEWS (Jan. 28, 2014),
http://www.hsph.harvard.edu/news/features/singapores-health-care-systemholds-lessons-for-u-s/ (synthesizing Haseltine’s book and the advantages of the
Singapore system). Singapore is known to have one of the world’s more
efficient and fair health care systems. The system has a policy of transparency
where all the information regarding a hospital or health care professional is
publically available, including the prices and fees associated with their
services. This allows patients to compare options and make an educated
decision for themselves. Although this policy is applied on a broader basis in
Singapore, for the whole health care system, it would be applicable to the
biosimilars market in the U.S. as well since there are many considerations
and a different choice might be right for each patient. See generally id.
202. See generally Addison, supra note 16, at 577; Kanter & Feldman,
supra note 7, at 74.
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applicant to first gain approval as a biosimilar;203 then, after
being on the market for a while without any indications of
safety concerns, the applicant may provide the FDA with
additional information such as efficacy and safety clinical data
to apply for interchangeability status.204 This is a departure
from the Biosimilars Act’s requirements, which allows an
applicant to file for interchangeability along with its 351(k)
application.205
Regardless of which approach is taken, there is bound to be
some disagreement among scientists, regulators, and the
general public about where the balance between accessibility
and precaution lies; therefore, the final policies require
“multilateral exchange” between experts, the FDA, and the
public.206 As noted by Sheila Jasanoff, there is a “grey zone
between science and policy or facts and values” such that “there
is no single right way to iron out the multiple ambiguities in
the regulatory record.”207
F. INSURANCE SUBSTITUTION STATUS
In order to increase the benefits of biosimilars at the state
level, it will be important for insurance companies to recognize
and reimburse biosimilars in coverage plans.208 This way, the
biosimilars will be interchangeable at the pharmacy and
insurance levels. One reason patients and doctors may be less
likely to select the biosimilar is if insurance companies do not
reimburse for the biosimilar as easily as they do for the
203. FDA QUESTIONS AND ANSWERS, supra note 26, at 2–3. Some argue
that this is not required by the Biosimilars Act, but is rather an additional
requirement by the FDA. The Biosimilars Act could be interpreted to mean
that an application for biosimilarity status is also an application for
interchangeability. This is a debate that health care officials, pharmacists,
and regulatory officials have been having for a while, where pharmacists are
pushing for fewer regulations that tie their hands and give them less
flexibility in prescribing drugs independently from the doctor. See Malkin,
supra note 67, at 89–90.
204. Kanter & Feldman, supra note 7, at 73–74 (arguing that the level of
clinical testing required for interchangeability is so stringent that it will lead
to more manufacturers filing for approval under the regular biologic approval
pathway—Biological License Application (BLA)).
205. Malkin, supra note 67, at 89.
206. See generally Sheila Jasanoff, Procedural Choices in Regulatory
Science, 17 TECH. SOC’Y 279, 290 (1995).
207. Id. at 292.
208. Interview with Ralph Hall, supra note 33.
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innovator biologics.209 Insurance is more likely to be available
for biosimilars if there is a publically available list of
biosimilars, that are “therapeutically equivalent” to their
innovator counterparts, as is done with small molecule
drugs.210 Without such an automatic substitution system in
place, the burden will be on the pharmacy and the patient to
contact the insurance provider to confirm acceptability of a
biosimilar, which will be onerous and hence seldom done.
CONCLUSION
This Note argues that the current state of biosimilar law is
overly burdensome for potential biosimilar developers and that
it provides a windfall for innovator biologics manufacturers.
This is due to extreme provisions and unclear guidelines
provided in the Biosimilars Act and by the FDA Draft Guidance
Documents. An effective and less burdensome biosimilars
approval pathway would increase accessibility and research for
important therapies; therefore, reforming the current system
must be a high priority for policy makers and experts. This
Note suggests six possible ways to reform the current law and
guidance around biosimilars and insists that a balance must be
struck between reducing risk and increasing accessibility of
biosimilars by engaging medical experts, law makers, and the
general public in dialogue as well as looking to the wellestablished approval processes of other countries.

209. See generally Aslam H. Anis, Substitution Laws, Insurance Coverage,
and Generic Drug Use, 32 MED. CARE 240 (1994).
210. U.S. DEP’T HEALTH & HUMAN SERVS., EXPANDING THE USE OF
GENERIC DRUGS 8–9 (2010), available at http://aspe.hhs.gov/sp/reports/2010
/genericdrugs/ib.pdf.

